Dendritic cells pulsed with CTP-fused tumor antigens enhanced immune cell activation and glioblastoma killing, with additive effects when combined with PD-1 blockade.
Additive with PD-1CTP-fused antigen vaccine enhanced glioblastoma cell killing, with further improvement when combined with checkpoint blockade
What the researchers found
Dendritic cells pulsed with CTP-fused tumor antigens (WT1 and BIRC5) showed enhanced expression of MHC molecules and co-stimulatory markers, indicating better antigen presentation. The vaccine also shifted immune signaling toward Th1 cytokine polarization, which favors anti-tumor immunity.
The CTP-fused antigen approach increased the number of IFN-gamma-producing effector T cells. These T cells showed enhanced killing of glioblastoma target cells expressing the matching antigens.
Combining the vaccine with PD-1 blockade further improved the cytotoxic T lymphocyte response, suggesting the two approaches work better together than either alone.
Why it matters
Glioblastoma is the deadliest brain cancer with a median survival of about 15 months. Current treatments rarely provide long-term control. A vaccine that effectively trains the immune system to recognize and kill glioblastoma cells could extend survival.
The CTP fusion approach solves a key problem in vaccine design by keeping the antigen in the cytoplasm where it can be processed and presented to killer T cells more effectively.
The numbers in context
Enhanced MHC/co-stimulatory markers; Th1 polarization; increased IFN-gamma+ T cells; enhanced GBM cell lysis; PD-1 blockade additive
How the study worked
This was an in vitro study. Researchers confirmed WT1, BIRC5, and PDL1 expression on glioblastoma cells by western blot. They pulsed mature dendritic cells with CTP-fused protein antigens and characterized them by flow cytometry and ELISA. Cytotoxic T lymphocyte activity was measured by IFN-gamma ELISPOT and lactate dehydrogenase release assays.
Who was studied
Glioblastoma cell lines and dendritic cell cultures
What this study cannot tell us
This was entirely an in vitro study. No animal models or patient data were included. Whether this approach would work against glioblastoma in a living brain, with its immune-suppressive environment, is unknown.
The study did not test whether CTP-fused antigens would work with naturally occurring, patient-derived dendritic cells.
How to read the evidence
Preliminary evidence from in vitro studies only. No animal model or patient data.
When this study was published
Published in 2020. Glioblastoma immunotherapy research continues with multiple combination approaches in clinical trials.
The bigger picture
Glioblastoma has the worst prognosis of any common cancer. Combining a dendritic cell vaccine with checkpoint inhibitors addresses both sides of the immune equation: the vaccine teaches immune cells what to attack, while PD-1 blockade prevents the tumor from suppressing the attack.
Questions still open
- Would this combination work in a glioblastoma animal model?
- Which tumor antigens beyond WT1/BIRC5 should be included in a multi-target vaccine?
- Can the CTP approach be scaled for clinical-grade dendritic cell manufacturing?
Common questions
What is a dendritic cell vaccine?
Why combine a vaccine with PD-1 blockade?
Read the original research
Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1.
Human vaccines & immunotherapeutics, 16(11), 2840-2848
Citation
Kim, Young-Hee; Tran, Thi-Anh-Thuy; Duong, Thi-Hoang-Oanh; Jung, Shin; Kim, In-Young; Moon, Kyung-Sub; Jang, Woo-Youl; Lee, Hyun-Ju; Lee, Je-Jung; Jung, Tae-Young. (2020). Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1.. Human vaccines & immunotherapeutics, 16(11), 2840-2848. https://doi.org/10.1080/21645515.2020.1732165